

| Description | Source | Experimental setting | Species | Used for parameter estimation | Figure |
|--|--------|----------------------|---------------------------|-------------------------------|--------|
| Fluid-phase inactivation of C3 in presence and absence of FI, FH, FB, FD | [1] | In vitro | Human proteins | No | 2A |
| C3 conversion to C3b by C3bBb | [2] | | Human proteins | No | 2B |
| Cleavage of C3b by fixed concentrations of FI and FH | [3] | | Human proteins | No | 2C |
| Spontaneous C3a formation in serum samples | [4] | | Human serum | No | 2D |
| Spontaneous C3a formation in serum samples | [5] | | Human serum | No | 2D |
| Spontaneous Bb and C3dg formation in serum samples | [6] | | Human serum | No | 2E,F |
| Linking terminal pathway activity to hemolysis | [7] | | Various | No | 3 |
| Time course of rabbit erythrocyte lysis | [8] | | Rabbit cells, human serum | Yes | 4A |
| Rabbit erythrocyte lysis as a function of FD and C3 titration and of FD titration at two different time points | | | | | 4C,D |
| Rabbit erythrocyte lysis at different serum concentrations | [9] | | Rabbit cells, human serum | Yes | 4B |
| Rabbit erythrocyte lysis as a function of C5, FB, FD titration | [10] | | Rabbit cells, human serum | No | 4E |
| Bb and C5a production due to rabbit erythrocyte lysis | | | | | 4F |
| Human erythrocyte lysis with inhibition of FH, DAF, CD59 | [11] | | Human | Yes | 5A |
| Human erythrocyte lysis with inhibition of FH, DAF, properdin | [12] | | Human | Yes | 5A |
| Human erythrocyte lysis with inhibition of CD59, DAF | [13] | Human | Yes | 5A | |
| Human PNH erythrocyte lysis as a function of eculizumab titration | [14] | Human | No | 6A | |
| Recovery of hemoglobin in patients with PNH on eculizumab treatment | [15] | In vivo | Human | No | 6B |

References

1. Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. *J Exp Med*. 1981;154: 856–67.
2. Pangburn MK, Müller-Eberhard HJ. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. *Biochem J*. 1986;235: 723–30.
3. Pangburn MK, Müller-Eberhard HJ. Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factors H and I. *Biochemistry*. 1983;22: 178–85.
4. Morad HOJ, Belete SC, Read T, Shaw AM. Time-course analysis of C3a and C5a quantifies the coupling between the upper and terminal Complement pathways in vitro. *J Immunol Methods*. 2015;427: 13–8.
5. Sagar A, Dai W, Minot M, LeCover R, Varner JD. Reduced order modeling and analysis of the human complement system. *PLoS One*. 2017;12: e0187373.
6. Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. *Mol Immunol*. 2013;56: 232–9.
7. Takeda J, Kozono H, Takata Y, Hong K, Kinoshita T, Sayama K, et al. Number of hits necessary for complement-mediated hemolysis. *Microbiol Immunol*. 1986;30: 461–8.
8. Wu X, Hutson I, Akk AM, Mascharak S, Pham CTN, Hourcade DE, et al. Contribution of Adipose-Derived Factor D/Adipsin to Complement Alternative Pathway Activation: Lessons from Lipodystrophy. *J Immunol*. 2018;200: 2786–2797.
9. Pangburn MK. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. *J Immunol*. 2002;169: 4702–6.
10. Thanassi JA, Dharaben P, Yang G, Galvan M, Yhao Y, Fabrycki J, et al. Comparison of complement functional assays: Differential sensitivities of hemolysis and Wieslab assays to levels of complement proteins C5, factor B, and factor D. XXVI ICW Kanazawa. 2016. pp. 1035–1226.
11. Ferreira VP, Pangburn MK. Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. *Blood*. 2007;110: 2190–2.
12. Leshner AM, Zhou L, Kimura Y, Sato S, Gullipalli D, Herbert AP, et al. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. *J Am Soc Nephrol*. 2013;24: 53–65.
13. Wilcox LA, Ezzell JL, Bernshaw NJ, Parker CJ. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum. *Blood*. 1991;78: 820–9.
14. Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, et al. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. *Blood*. 2017;129: 970–980.
15. Choi CW, Jang JH, Kim JS, Jo D-Y, Lee J-H, Kim S-H, et al. Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. *Blood Res*. 2017;52: 207–211.